

Can dynamic imaging, using ^{18}F -FDG PET/CT and CT perfusion differentiate between benign and malignant pulmonary nodules?

Aleksander Marin^{1,2}, John T. Murchison³, Kristopher M. Skwarski⁴, Adriana A.S. Tavares¹, Alison Fletcher¹, William A. Wallace⁵, Vladka Salapura², Edwin J.R. van Beek¹, Saeed Mirsadraee^{1,6}

¹ Edinburgh Imaging facility Queens Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom

² Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

³ Department of Radiology, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom

⁴ Department of Respiratory Medicine, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom

⁵ Department of Pathology, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom

⁶ National Heart and Lung Institute, Imperial College London, London, United Kingdom

Radiol Oncol 2021; 55(3): 259-267.

Received 26 March 2021

Accepted 24 April 2021

Correspondence to: Aleksander Marin, M.D., Radiology Department, University Hospital Llandough, Penlan Road, Penarth CF64 2XX, United Kingdom. E-mail: aleksander.marin@wales.nhs.uk

Disclosure: No potential conflicts of interest were disclosed.

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Background. The aim of the study was to derive and compare metabolic parameters relating to benign and malignant pulmonary nodules using dynamic 2-deoxy-2-[fluorine-18]fluoro-D-glucose (^{18}F -FDG) PET/CT, and nodule perfusion parameters derived through perfusion computed tomography (CT).

Patients and methods. Twenty patients with 21 pulmonary nodules incidentally detected on CT underwent a dynamic ^{18}F -FDG PET/CT and a perfusion CT. The maximum standardized uptake value (SUV_{max}) was measured on conventional ^{18}F -FDG PET/CT images. The influx constant (K_i) was calculated from the dynamic ^{18}F -FDG PET/CT data using Patlak model. Arterial flow (AF) using the maximum slope model and blood volume (BV) using the Patlak plot method for each nodule were calculated from the perfusion CT data. All nodules were characterized as malignant or benign based on histopathology or 2 year follow up CT. All parameters were statistically compared between the two groups using the nonparametric Mann-Whitney test.

Results. Twelve malignant and 9 benign lung nodules were analysed (median size 20.1 mm, 9–29 mm) in 21 patients (male/female = 11/9; mean age \pm SD: 65.3 ± 7.4 ; age range: 50–76 years). The average SUV_{max} values \pm SD of the benign and malignant nodules were 2.2 ± 1.7 vs. 7.0 ± 4.5 , respectively ($p = 0.0148$). Average K_i values in benign and malignant nodules were 0.0057 ± 0.0071 and $0.0230 \pm 0.0155 \text{ min}^{-1}$, respectively ($p = 0.0311$). Average BV for the benign and malignant nodules were 11.6857 ± 6.7347 and $28.3400 \pm 15.9672 \text{ ml}/100 \text{ ml}$, respectively ($p = 0.0250$). Average AF for the benign and malignant nodules were 74.4571 ± 89.0321 and $89.200 \pm 49.8883 \text{ ml}/100\text{g}/\text{min}$, respectively ($p = 0.1613$).

Conclusions. Dynamic ^{18}F -FDG PET/CT and perfusion CT derived blood volume had similar capability to differentiate benign from malignant lung nodules.

Key words: pulmonary nodule, perfusion, CT, dynamic, PET/CT

Introduction

Pulmonary nodules are detected with increasing frequency due to widespread use of computed to-

mography (CT).^{1,2} The prevalence of incidental pulmonary nodules on standard CT studies is around 13%, while lung cancer screening will detect lung nodules in up to 53% of subjects, leading to a lung

cancer prevalence of around 1.4% (0.5–2.7%).³ The optimal diagnostic approach for the management of indeterminate pulmonary nodules has been the subject of much discussion.⁴

The widely accepted guidelines published by the British Thoracic Society (BTS) and the Fleischner Society recommend the minimum nodule diameter thresholds and CT follow-up time intervals for surveillance of solitary nodules smaller than 8 mm.^{3,5} For nodules of ≥ 8 mm (300 mm³), the BTS guidelines recommend risk assessment using the Brock model. The above guidelines recommend either 3-month CT follow-up, work-up with positron emission tomography (PET) with 2-deoxy-2-[fluorine-18]fluoro-D-glucose (¹⁸F-FDG), tissue sampling, or resection for nodules of ≥ 8 mm. CT characterisation using only morphological features is imprecise^{6,7}, leading to an increased interest in computer-based radiomics assessment.^{8–15} Serial CT imaging to monitor nodule size can be problematic as nodule growth varies with different cancers and causes patient anxiety.^{16–18} ¹⁸F-FDG PET has high sensitivity but lower specificity of 82% for detecting malignant pulmonary nodules, particularly in those smaller than 10 mm.¹⁹ Imaging guided sampling of small nodules is also difficult, is associated with complications, and its diagnostic yield decreases further as nodule size decreases.^{3,20,21}

Neovascularisation is a complex process known to be central to carcinogenesis.²² Advances in the imaging technology in the last two decades have enabled the study of perfusion characteristics within pulmonary nodules.^{23–27} As benign and malignant lesions have different vascularity, different perfusion parameters and dynamic ¹⁸F-FDG uptake properties can be expected.^{27–32}

The purpose of this pilot study was to evaluate the feasibility and accuracy of CT perfusion and dynamic ¹⁸F-FDG PET imaging in differentiating proven benign and malignant pulmonary nodules.

Patients and methods

This single-centre prospective study was approved by the local Research Ethics Committee (13/SS/0153) and written informed consent was obtained from all participants.

Between December 2014 and December 2015, 20 consecutive patients who were referred to our respiratory outpatient clinic for an indeterminate incidental pulmonary nodule were recruited. The inclusion criteria were: a) incidentally detected soft tissue (solid) pulmonary nodules measuring ≥ 8

mm and < 30 mm on CT, b) either surgical excision, imaging guided biopsy or imaging follow up of the nodule planned. The exclusion criteria were: a) abnormal renal function, b) previous adverse reaction to iodinated contrast agent, c) known history of malignancy, d) pregnancy or breast feeding, e) patients who refused or were unable to provide informed consent.

The patients underwent a dynamic ¹⁸F-FDG PET/CT and dynamic perfusion CT imaging within a 3 week time frame (mean, 6.4 days: range 1–18 days). Due to technical reasons, the dynamic PET data could not be used in 4 patients for the analysis, one of these patients had two synchronous nodules. CT perfusion analysis was performed in 17 of the nodules. One patient declined the CT perfusion scan and 3 patients had significant breathing artefact on the scans, rendering analysis non-feasible. All nodules were classified into either benign or malignant on the basis of a histopathological diagnosis (n = 16), or stability during 2 years follow up CT imaging (n = 5).

Dynamic PET/CT image acquisition

All patients were fasted for at least six hours before the imaging. Following a low dose CT scan for attenuation correction and localisation (120 kV, 50 mAs, 5/3 mm), patients were administered 400 MBq of ¹⁸F-FDG intravenously, and a dynamic 60 minute image acquisition was performed using a Siemens Biograph PET/CT scanner (Siemens Healthcare, Erlangen, Germany). Respiratory-gated PET data were reconstructed using a 15-frame protocol (7 frames \times 180 s, 7 \times 300 s, 1 \times 240 s), a matrix size of 256 \times 256 \times 53 with a voxel size of 2.65 \times 2.65 \times 3.00 mm³, and subsets expectation maximization (OSEM) method. A conventional PET/CT scan was performed on completion of the dynamic phase of the scan at 1 hour after injection of the tracer.

Perfusion volume CT acquisition

Dynamic perfusion CT scans were performed as previously described^{25,28,33,34} on a 320-detector row CT scanner (Aquilion ONE; Toshiba Medical Systems, Tokyo, Japan) with 16 cm field of view coverage. Imaging was performed at 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 30, 40, 50, 60, 90, 120 seconds, 3 minutes, 4 minutes, and 10 minutes following the intravenous injection of 70 ml of iodinated contrast (Iomeron 400 mg/ml, Bracco, Milan, Italy) followed by a 30 ml bolus of saline both at 9 ml/s through a 16 G cannula sited in the ante cubital fos-

sa. Acquisition parameters were 100 kV, 100 mA, 0.5 seconds rotation time, 320 x 0.5 mm collimation, 512 x 512 matrix.

Image analysis

Dynamic PET/CT

Reconstructed images were imported into PMOD 3.409 software (PMOD Technologies, Zurich, Switzerland) and the input function was determined by placing a spherical volume of interest (VOI) with diameter of 1 cm in the ascending aorta. VOIs were drawn around the pulmonary nodules semi-automatically with a threshold of 50% of the maximum voxel value within the nodule, and then the VOIs were copied to the dynamic imaging sequence to obtain the time activity curves (TACs) (Figure 1). The influx constant K_i (min^{-1} or $(\text{ml plasma}) \cdot (\text{ml tissue})^{-1} \cdot \text{min}^{-1}$) was determined by Patlak analysis.³⁵ The Patlak plot model is a graphical analysis technique based on a 2-tissue compartment model with irreversibly trapped tracer. A mathematical transformation of the tissue compartment and plasma TACs produces a straight line plot which provides information about the blood volume (BV) of the tissue compartment and the exchange rate (K_i) (Figure 2).

Conventional PET/CT scan

The maximum standardised uptake value (SUV_{max}) was measured for each nodule on conventional FDG PET/CT images. For the semi-quantitative analysis, the mean standardised uptake values (SUV_{mean}) were measured of the ascending aorta at the level of the arch, and within the right lobe of the liver. SUV ratios (SUR) were calculated between the nodule SUV_{max} and the SUV_{mean} of the mediastinal blood pool ($\text{SUR}_{\text{BLOOD}}$) and liver ($\text{SUR}_{\text{LIVER}}$). Criteria for malignancy were specified as $\text{SUV}_{\text{max}} \geq 2.5$; $\text{SUR}_{\text{BLOOD}} \geq 1.56$; $\text{SUR}_{\text{LIVER}} \geq 1.12$. Qualitative assessment PET features were specified as following: 0 = no visible uptake; 1 = uptake less than mediastinal blood pool; 2 = uptake comparable to mediastinal blood pool; 3 = uptake greater than mediastinal blood pool; 4 = distant metastases. Qualitative specified criteria for malignancy was PET grade ≥ 3 .^{36,37} VOIs were placed over the nodules, the ascending aorta at the level of the arch, and within the right lobe of the liver for determination of the SUV_{mean} and SUV_{max} values using OsiriX software (OsiriX, version 8.0.1 64 bit; OsiriX Imaging Software, Geneva, Switzerland).




FIGURE 1. Dynamic PET images of a small pulmonary nodule in the left upper lobe and corresponding time activity curve (TAC) of the nodule displayed by PMOD 3.409 software.




FIGURE 2. Patlak plot derived from the tissue time activity curve (TAC) and the input function (plasma TAC). The Patlak plot becomes linear after the tracer concentrations in reversible compartments and in plasma are in steady state.

Perfusion CT

Perfusion analysis was performed using Body Perfusion Application on a Vitrea Workstation (Vitrea fx 6.0; Vital Images, Minnetonka, MN, USA). Regions of interest (ROIs) were placed over the pulmonary nodules and contralateral lung parenchyma (diameter range, 7–29 mm) on all perfusion CT images. Arterial input was determined by placing 1 cm ROI over the main pulmonary

TABLE 1. The demographic data, average nodule size, standardized uptake value (SUV_{max}), metabolic parameter relating to the pulmonary nodules through dynamic ^{18}F -FDG PET/CT, and perfusion parameters through perfusion CT for the benign and malignant nodules

	Benign Nodules	Malignant Nodules	p value
Total Number of nodules	9	12	
Number of male patients (%)	5/9 (55 %)	6/12 (50 %)	
Average patient age (years \pm SD)	63 \pm 7.5	68 \pm 6.7	
Average nodule size, range (mm)	18, 9–29	22, 12–30	
Average SUV_{max} ^{18}F -FDG PET/CT \pm SD	2.2 \pm 1.7	7.0 \pm 4.5	0.0148
Number of nodules analysed for dynamic ^{18}F -FDG PET/CT	7	9	
Average K_i \pm SD (min^{-1})	0.0057 \pm 0.0071	0.0230 \pm 0.0155	0.0311
Number of nodules analysed for perfusion CT parameters	7	10	
Average BV \pm SD (Patlak, ml/100ml)	11.6857 \pm 6.7347	28.3400 \pm 15.9672	0.0250
Average AF \pm SD (ml/100g/min)	74.4571 \pm 89.0321	89.2000 \pm 49.8883	0.1613

AF = Arterial flow; BV = blood volume; K_i = influx constant; SD = standard deviation; SUV = standardized uptake value

artery. Time-density graphs were then reviewed and adjustments to start point and end point of the maximum slope were made if needed to define the optimal slope range. Arterial flow perfusion maps overlaying CT images were visually analysed and ROIs were placed over the nodules to obtain the equivalent blood volume parameter calculated by Patlak plot model (BV, expressed in ml per 100 ml) and Arterial Flow (AF, expressed in ml per 100g per minute) using single-input maximum slope model for calculation.

Statistical analysis

All results were expressed as mean \pm standard deviation (SD) unless indicated. K_i and perfusion indices BV and AF of benign and malignant nodules were statistically compared using the nonparametric Mann-Whitney U test. The accuracy of the different techniques and parameters was tested with area under the curve (AUC) in receiver operating characteristic (ROC) analysis with 95% confidence interval (CI). Comparison between the ROCs was performed using DeLong's test. Youdin index analysis was used to derive the optimised cut-point values. Mann-Whitney U test and ROC curve analyses were performed on GraphPad Prism version 8.2.1 for Windows (GraphPad Software, San Diego, CA, USA). Youdin index analysis and nonparametric DeLong's test were performed on MedCalc Statistical Software version 19.8 (MedCalc Software Ltd, Ostend, Belgium; <https://www.medcalc.org/>;

2021). A p value $<$ 0.05 was considered statistically significant.

Results

The demographic data, average nodule size, SUV_{max} , metabolic parameter relating to the pulmonary nodules through dynamic ^{18}F -FDG PET/CT, and perfusion parameters through perfusion CT for the benign and malignant nodules are summarised in Table 1 and Figure 3. We analysed 21 soft tissue nodules in 20 patients (male/female = 11/9; mean age \pm SD: 65.3 \pm 7.4; age range: 50–76 years) with mean nodule diameter \pm SD of 20.1 \pm 7.5 mm (9–29 mm); mean nodule volume \pm SD: 2849 \pm 2338.7 mm³ (247–9348 mm³). 52% of the nodules were located in the upper lung lobes (right upper lobe 7/21, left upper lobe 4/21), 48% were in middle and lower lung lobes (right middle lobe 2/21, right lower lobe 6/21 and left lower lobe 2/21). Final diagnosis was determined after surgical resection in 10 patients, core CT guided biopsy or bronchoscopy in 6 patients, and over 2 years stability on follow up CT imaging in 5 patients.

As shown in Table 1 and Figure 3, SUV_{max} derived from the conventional ^{18}F -FDG PET/CT and K_i derived from dynamic ^{18}F -FDG PET/CT were significantly higher in malignant nodules than in benign nodules. Also, the Patlak model derived BV on perfusion CT was significantly higher in malignant nodules. The difference in AF between




FIGURE 3. (A) standardized uptake value (SUV_{max}), (B) Dynamic ^{18}F -FDG PET/CT influx constant (K_i), (C) Perfusion CT parameters blood volume (BV) and (D) Average arterial flow (AF) of the benign and malignant nodules.

the benign nodules and malignant nodules was not statistically significant.

The benign outlier on ^{18}F -FDG PET/CT ($SUV_{max} = 6.3$) and dynamic ^{18}F -FDG PET/CT ($K_i = 0.0179 \text{ min}^{-1}$) was an 18 mm nodule of inflammation and fibrosis (Figure 3A and B). The perfusion CT indices BV and AF in this nodule were relatively low, 3.8 ml/100ml and 51.5 ml/100g/min, respectively (Figure 3C and D). The two malignant outliers on conventional ^{18}F -FDG PET/CT and dynamic ^{18}F -FDG PET/CT were 12 mm and 16 mm mucinous adenocarcinomas *in situ* (12 mm nodule with $SUV_{max} = 0.7$ and $K_i = 0.0015 \text{ min}^{-1}$ (BV and AF analysis non-feasible due to respiratory motion artefact); 16 mm nodule with $SUV_{max} = 1.0$, $K_i = 0.0033$

min^{-1} , BV = 48.8 ml/100ml and AF = 154.1 ml/100g/min) (Figure 3A and B). The mean CT densities of these two nodules on unenhanced CT images were 16.3HU and 15.9HU, while the mean density \pm SD of all benign and malignant nodules analysed was 24.55 ± 12.01 HU. The benign outlier in AF on perfusion CT was a 10 mm perivascular epithelioid cell tumour (PEComa), AF = 272.7 ml/100g/min (Figure 3D). The BV in this nodule was 20.5 ml/100ml, the ^{18}F -FDG PET/CT indices were low, $SUV_{max} = 0.7$ and the $K_i = 0.001 \text{ min}^{-1}$.

Table 2 and Figure 4A show diagnostic accuracy of conventional PET/CT derived parameters with pre-specified and derived cut-point values though ROC analysis.^{36,37} SUR_{BLOOD} parameter had overall

TABLE 2. Comparison of the diagnostic accuracy of different techniques and parameters with pre-specified and derived cut-point values for malignancy

Parameter	Cut-point value/grade	Sensitivity (95% CI)	Specificity (95% CI)	Accuracy
SUV_{max}	Pre-specified $\geq 2.5^*$	75.0% (46.8 to 91.1%)	66.7% (35.4 to 87.9%)	71.4%
	Derived ≥ 3.4	75.0% (46.8 to 91.1%)	88.9% (56.5 to 99.43%)	81.0%
SUR_{BLOOD}	Pre-specified ≥ 1.56	83.3% (55.2 to 97.0%)	88.9% (56.5 to 99.4%)	85.7%
	Derived ≥ 1.65	75.0% (46.8 to 91.1%)	88.9% (56.5 to 99.4%)	81.0%
SUR_{LIVER}	Pre-specified ≥ 1.12	83.3% (55.2 to 97.0%)	66.7% (35.4 to 87.9%)	76.2%
	Derived ≥ 1.65	75.0% (46.8 to 91.1%)	88.9% (56.5 to 99.4%)	81.0%
SUV_{grade}	Pre-specified & Derived ≥ 3	66.7% (39.0 to 86.2%)	77.8% (45.3 to 96.0%)	71.4%
K_i	Derived $\geq 0.01 \text{ min}^{-1}$	77.8% (45.2 to 96.0%)	85.7% (48.7 to 99.3%)	81.3%
BV	Derived $\geq 21 \text{ ml/100ml}$	70% (39.7 to 89.2%)	100% (64.6 to 100%)	82.4%
AF	Derived $\geq 65 \text{ ml/100g/min}$	70% (39.7 to 89.2%)	85.7% (48.7 to 99.3%)	76.5%

* = adding cut-points standardized uptake value (SUV_{max}) ≥ 1.75 and ≥ 3.6 for nodules $< 12 \text{ mm}$ and $> 16 \text{ mm}$, respectively,³⁷ resulted in sensitivity, specificity and accuracy of 72.7%, 70.0% and 71.4%, respectively;

AF = Arterial flow; BV = blood volume; CI = confidence interval; K_i = influx constant; SUR = SUV ratios; SUV = standardized uptake value




FIGURE 4. Comparison of AUCs on ROC curves (A) SUV_{max} , SUR_{BLOOD} , SUR_{LIVER} , PET grade and (B) SUR_{LIVER} , K_i , BV and AF.

95% CI, p values for SUV_{max} / SUR_{BLOOD} / SUR_{LIVER} / PET grade / K_i / BV / AF: 0.6264 to 1.000, 0.0157/ 0.6486 to 1.000, 0.0105/ 0.6550 to 1.000, 0.0105/ 0.507 to 0.956, 0.0756/ 0.602 to 1.000, 0.0300/ 0.6322 to 1.000, 0.0248/ 0.4342 to 0.9944, 0.1432.

highest accuracy, however, pairwise comparison of AUCs showed no significant difference ($p = 0.5308$ vs. SUV_{max} ; $p = 1.0000$ vs. SUR_{LIVER} ; $p = 0.1083$ vs. PET grade). ROC analysis and diagnostic accuracy for the diagnosis of malignancy by dynamic ^{18}F -FDG PET/CT parameter K_i and perfusion CT indices BV and AF compared to SUR_{BLOOD} are further detailed in Table 2 and Figure 4B. Pairwise comparison of AUCs of SUR_{BLOOD} , K_i , BV and AF showed no significant difference in their diagnostic performances ($p > 0.1$ for all comparisons).

Discussion

Our results demonstrate that the metabolic parameter K_i of dynamic ^{18}F -FDG PET/CT and the BV parameter of perfusion CT are significantly lower in benign nodules.

Our study showed that the diagnostic accuracy of the conventional ^{18}F -FDG PET/CT was best when semi-quantitative assessment and measuring the uptake ratio of the lung nodule to the mediastinal blood pool with cut-point criteria for malignancy $SUR_{BLOOD} \geq 1.56$ was used. This has been confirmed in a larger multicenter trial by Evangelista *et al.*³⁶ Different to the SPUTNIK trial which has shown SUV_{max} to be the most accurate and reproducible technique with a caveat of introducing additional cut-point values altered according to the nodule size, we did not see significant improvement in diagnostic accuracy when replicating the multiple cut-points in our group of nodules (see * in Table 2).³⁷

The accuracies of the new metabolic parameter K_i and perfusion parameter BV were not signifi-

cantly different to the conventional ^{18}F -FDG PET/CT. The derived K_i cut-point for malignancy was $\geq 0.01 \text{ min}^{-1}$ resulting in sensitivity/specificity/accuracy of 77.8%/85.7%/81.3%, respectively. This is in good agreement with K_i cut-point $\geq 0.014 \text{ min}^{-1}$ reported in the study by Huang *et al.* ($n = 35$).²⁶ The derived BV cut-point value of $\geq 21 \text{ ml/100ml}$ for malignancy showed comparable diagnostic accuracy to conventional and dynamic ^{18}F -FDG PET/CT parameters. The high specificity of BV demonstrated in our nodules would need to be confirmed in larger studies.

The benign outlier on dynamic ^{18}F -FDG PET/CT with a high K_i parameter histopathologically represented inflammation (Figure 3B). Higher metabolic activity is not only a feature of malignant cells, it can be observed in inflammatory nodules due to increased glucose metabolism in granulocytes and macrophages in a range of diseases, including fungal and necrobiotic rheumatoid nodules, sarcoidosis, tuberculosis, and other granulomas.^{38,39} Dual time PET/CT did not prove to be useful for differentiating benign and malignant pulmonary nodules with an SUV_{max} less than 2.5 in regions with high prevalence of granulomatous disease.^{40,41} Huang *et al.* showed that dynamic ^{18}F -FDG PET/CT is valuable in differentiating benign from malignant pulmonary nodules with the potential to differentiate malignant from granulomatous disease.²⁶ Our study showed limited diagnostic accuracy of the dynamic ^{18}F -FDG PET/CT in assessing inflammatory nodules.

The malignant outliers on dynamic ^{18}F -FDG PET/CT with low K_i parameters were histopathologically mucinous adenocarcinoma *in situ*. Other malignant nodules in which low metabolic activity can be measured on ^{18}F -FDG PET/CT are minimally invasive adenocarcinoma, carcinoid, and lung lymphoma.^{38,42} Another important finding was that both malignant nodules with low metabolic activity were of lower CT density analysed on the initial perfusion CT images but also appreciable on low-dose CT scan of PET/CT examination. Further studies on low density lung nodules are needed for evaluation of using lower cut-point values for malignancy in conventional and dynamic PET/CT. Malignant lung nodules with low CT density and measuring less than 1 cm are known to have low metabolic activity on conventional ^{18}F -FDG PET/CT.^{43,44} Berger *et al.* have reported up to 41% of lung lesions to be false-negative on conventional ^{18}F -FDG PET/CT in analysis of 25 mucinous, hypocellular lung lesions (3/9 false negative lesions were $\leq 2 \text{ cm}$, range, 1–5 cm).⁴⁵ Our study showed a

limited diagnostic accuracy of the dynamic ^{18}F -FDG PET/CT in assessing low density malignant pulmonary nodules with K_i cut-point set at 0.01 min^{-1} .

Dynamic enhancement CT studies help identify false positive results in both inflammatory and infective conditions, and sometimes in benign vascular tumours.^{46,47} The perfusion CT parameters for the inflammatory nodule in our study were low and indicative of a benign lesion despite high metabolic activity on ^{18}F -FDG PET/CT. We have shown that the parameters of perfusion CT of both malignant nodules with low metabolic activity were higher than the BV and AF in benign nodules. Therefore, our findings indicate parameters of perfusion CT may aid in the identification of benign nodules with high glucose metabolic activity and in the identification of malignant nodules with low glucose metabolic activity. Ohno *et al.* have shown that perfusion CT is more specific and accurate than conventional ^{18}F -FDG PET/CT.^{24,29} Our study on a small sample of cases suggests that perfusion CT also performs better than dynamic ^{18}F -FDG PET/CT.

The AF parameter of the perfusion CT obtained by the maximum slope method was not significantly different between benign and malignant nodules. Benign nodules had a lower AF parameter value than malignant nodules overall with one significant benign outlier with markedly high AF. Histopathologically, this represented an extremely rare 'light cell' or 'sugar type' PEComa. There are only about 50 cases of this neoplasm described in the literature.^{48,49} PEComas are more commonly found as angiomyolipomas in the kidneys, or as lesions in the retroperitoneal space, gastrointestinal tract, or uterus. Only 7 cases of malignant pulmonary PEComa have been reported.⁵⁰ A case report of a benign pulmonary PEComa showing early wash-in enhancement with an early washout pattern of a malignant lesion on perfusion CT has been reported by Kim *et al.*⁵¹ Despite a markedly high AF, the PEComa had a BV just under the cut-point value for malignancy and a low metabolic parameter K_i of dynamic ^{18}F -FDG PET/CT. The BV parameter in combination with low K_i parameter proved to be more reliable for defining this extremely rare histological type of a pulmonary nodule.

Our study has limitations. This pilot study was performed in a small sample of patients and appropriately powered studies will be required for further validation. The mean nodule size was 18 mm for benign and 22 mm for malignant nodules, which would not normally be referred for imaging follow-up. The BTS and Fleischner Society recommended lower thresholds for nodule follow up (5

mm and 6 mm, respectively). More novel reconstruction methods in PET/CT such as specific point spread function (PSF) are enabling better spatial resolution and enable its use in 6 mm pulmonary nodules.⁵²

Perfusion CT is quite demanding on patients with a prolonged breath-hold, which limits the availability of reliable data in some patients. All 3 nodules in which analysis was non-feasible due to the significant breathing artefact were near the diaphragm (2 in the right lower lobe and 1 in the right middle lobe). Segmentation of the pulmonary nodules on image analysis is restricted when the images were affected by respiratory motion artefact, especially in small nodules which were also abutting the chest wall or mediastinal structures. Some authors recommend quiet breathing during the perfusion CT scans but this is only acceptable in larger lung masses.⁵³ There is a need for further optimisation of nodule segmentation and advanced image registration techniques that allow accurate assessment of pulmonary nodules without need for long breath-hold.^{23,54} The effective radiation dose for dynamic ^{18}F -FDG PET/CT was around 8 mSv and for perfusion CT around 20 mSv. The radiation dose for perfusion CT can be improved by reducing the field of view from 16 cm to the nodule only and reducing tube voltage in smaller size patients.⁵⁵

Potential increase in the demand for these not widely available novel dynamic imaging studies would consequently put additional strain on the imaging departments with increased demand for scanner time, funding and training of the staff. Limited capacity for a wider use of the dynamic imaging in lung nodules could be overcome by developing systems of identification of nodules with highest diagnostic benefit from dynamic imaging. A multicentre prospective cohort observational study initiated in 2016 is set to assess the performance and the cost-effectiveness of the dynamic CT and PET/CT in the characterisation of solitary pulmonary nodules.⁵⁶

The small sample size limits the assessments of accuracy in our study. However, on this small sample we showed increase diagnostic improvement in the accuracy of diagnosis in both dynamic studies when compared to the conventional ^{18}F -FDG PET/CT. Specificity in K_i and BV on our small sample size were higher at the estimated threshold values of 0.01 min^{-1} and 21 ml/100ml, respectively. This would need to be confirmed in larger studies.

Early identification of a lung nodule as benign or malignant by analysing its metabolic and per-

fusion parameters could reduce the need for CT to monitor lung nodule size, thereby reducing the number of CT scans required. It could also reduce the need for CT guided biopsy or other invasive procedures. Patients with malignant lung nodules could thus be identified more quickly and referred for radical treatment. With our study, we have demonstrated the potential of perfusion CT. The BV parameter assessed by perfusion CT was not only significantly lower in benign nodules, it also aided in correctly characterising the metabolically active inflammation, hypervascular benign PEComa and low density malignancy.

In conclusion, this study demonstrated the feasibility of dynamic ¹⁸F-FDG PET/CT and CT perfusion studies in differentiating benign and malignant pulmonary nodules. The dynamic ¹⁸F-FDG PET/CT and perfusion CT derived blood volume can assist to differentiate benign and malignant lung nodules and in indeterminate cases, a combined approach can be helpful.

Acknowledgments

The authors would like to thank the late Martin Connell for his curiosity and analytical contribution; Dr. Dilip Patel, Dr. William Walker and the radiographers of the Queen's Medical Research Institute in Edinburgh for their support in this study.

References

1. Furtado CD, Aguirre DA, Sirlin CB, Dang D, Stamato SK, Lee P, et al. Whole-body CT screening: spectrum of findings and recommendations in 1192 patients. *Radiology* 2005; **237**: 385-94. doi: 10.1148/radiol.2372041741
2. Brenner DJ, Hall EJ. Computed tomography – an increasing source of radiation exposure. *N Engl J Med* 2007; **357**: 2277-84. doi: 10.1056/nejra072149
3. Callister MEJ, Baldwin DR, Akram AR, Barnard S, Cane P, Draffan J, et al. British thoracic society guidelines for the investigation and management of pulmonary nodules. *Thorax* 2015; **70**: ii1-54. doi: 10.1136/thoraxjnl-2015-207168
4. Shinohara S, Hanagiri T, Takenaka M, Chikaishi Y, Oka S, Shimokawa H, et al. Evaluation of undiagnosed solitary lung nodules according to the probability of malignancy in the American College of Chest Physicians (ACCP) evidence-based clinical practice guidelines. *Radiol Oncol* 2014; **48**: 50-5. doi: 10.2478/raon-2013-0064
5. MacMahon H, Naidich DP, Goo JM, Lee KS, Leung ANC, Mayo JR, et al. Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner Society 2017. *Radiology* 2017; **284**: 228-43. doi: 10.1148/radiol.2017161659
6. Li F, Sone S, Abe H, MacMahon H, Armato SG, Doi K. Lung cancers missed at low-dose helical CT screening in a general population: comparison of clinical, histopathologic, and imaging findings. *Radiology* 2002; **225**: 673-83. doi: 10.1148/radiol.2253011375
7. Joo HO, Je RY, Sung HK, Hyung SS, Soo KC. Clinical significance of small pulmonary nodules with little or no ¹⁸F-FDG uptake on PET/CT images of patients with nonthoracic malignancies. *J Nucl Med* 2007; **48**: 15-21.
8. Chen S, Harmon S, Perk T, Li X, Chen M, Li Y, et al. Diagnostic classification of solitary pulmonary nodules using dual time ¹⁸F-FDG PET/CT image texture features in granuloma-endemic regions. *Sci Rep* 2017; **7**: 9370. doi: 10.1038/s41598-017-08764-7
9. Wilson R, Devaraj A. Radiomics of pulmonary nodules and lung cancer. *Transl Lung Cancer Res* 2017; **6**: 86-91. doi: 10.21037/tlcr.2017.01.04
10. Hawkins S, Wang H, Liu Y, Garcia A, Stringfield O, Krewer H, et al. Predicting malignant nodules from screening CT scans. *J Thorac Oncol* 2016; **11**: 2120-8. doi: 10.1016/j.jtho.2016.07.002
11. Xu Y, Lu L, Lin-Ning E, Lian W, Yang H, Schwartz LH, et al. Application of radiomics in predicting the malignancy of pulmonary nodules in different sizes. *Am J Roentgenol* 2019; **213**: 1213-20. doi: 10.2214/AJR.19.21490
12. Ather S, Kadir T, Gleeson F. Artificial intelligence and radiomics in pulmonary nodule management: current status and future applications. *Clin Radiol* 2020; **75**: 13-9. doi: 10.1016/j.crad.2019.04.017
13. Khawaja A, Bartholmai BJ, Rajagopalan S, Karwoski RA, Varghese C, Maldonado F, et al. Do we need to see to believe? – radiomics for lung nodule classification and lung cancer risk stratification. *J Thorac Dis* 2020; **12**: 3303-16. doi: 10.21037/jtd.2020.03.105
14. Feng B, Chen X, Chen Y, Liu K, Li K, Liu X, et al. Radiomics nomogram for preoperative differentiation of lung tuberculoma from adenocarcinoma in solitary pulmonary solid nodule. *Eur J Radiol* 2020; **128**: 109022. doi: 10.1016/j.ejrad.2020.109022
15. Palumbo B, Bianconi F, Palumbo I, Fravolini ML, Ministrini M, Nuvoli S, et al. Value of shape and texture features from ¹⁸F-FDG PET/CT to discriminate between benign and malignant solitary pulmonary nodules: an experimental evaluation. *Diagnostics* 2020; **10**: 696. doi: 10.3390/diagnostics10090696
16. Henschke CI, Yankelevitz DF, Yip R, Reeves AP, Farrowqi A, Xu D, et al. Lung cancers diagnosed at annual CT screening: volume doubling times. *Radiology* 2012; **263**: 578-83. doi: 10.1148/radiol.12102489
17. Koroscil MT, Bowman MH, Morris MJ, Skabelund AJ, Hersh AM. Effect of a pulmonary nodule fact sheet on patient anxiety and knowledge: a quality improvement initiative. *BMJ Open Qual* 2018; **7**: e000437. doi: 10.1136/bmjopen-2018-000437
18. Slatore CG, Wiener RS, Golden SE, Au DH, Ganzini L. Longitudinal assessment of distress among veterans with incidental pulmonary nodules. *Ann Am Thorac Soc* 2016; **13**: 1983-91. doi: 10.1513/AnnalsATS.201607-555OC
19. Cronin P, Dwamena BA, Kelly AM, Carlos RC. Solitary pulmonary nodules: Meta-analytic comparison of cross-sectional imaging modalities for diagnosis of malignancy. *Radiology* 2008; **246**: 772-82. doi: 10.1148/radiol.2463062148
20. Wu CC, Maher MM, Shepard JAO. Complications of CT-guided percutaneous needle biopsy of the chest: prevention and management. *Am J Roentgenol* 2011; **196**: W678-82. doi: 10.2214/AJR.10.4659
21. Huang MD, Weng HH, Hsu SL, Hsu LS, Lin WM, Chen CW, et al. Accuracy and complications of CT-guided pulmonary core biopsy in small nodules: a single-center experience. *Cancer Imaging* 2019; **19**: 51. doi: 10.1186/s40644-019-0240-6
22. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? – G. H. A. clowes memorial award lecture. *Cancer Res* 1986; **46**: 467-73. PMID: 2416426
23. Cavalcanti PG, Shirani S, Scharcanski J, Fong C, Meng J, Castelli J, et al. Lung nodule segmentation in chest computed tomography using a novel background estimation method. *Quant Imaging Med Surg* 2016; **6**: 16-24. doi: 10.3978/j.issn.2223-4292.2016.02.06
24. Ohno Y, Nishio M, Koyama H, Seki S, Tsubakimoto M, Fujisawa Y, et al. Solitary pulmonary nodules: comparison of dynamic first-pass contrast-enhanced perfusion area-detector CT, dynamic first-pass contrast-enhanced MR imaging, and FDG PET/CT. *Radiology* 2015; **274**: 563-75. doi: 10.1148/radiol.14132289
25. Ohno Y, Nishio M, Koyama H, Miura S, Yoshikawa T, Matsumoto S, et al. Dynamic contrast-enhanced CT and MRI for pulmonary nodule assessment. *Am J Roentgenol* 2014; **202**: 515-29. doi: 10.2214/AJR.13.11888

26. Huang YE, Lu HI, Liu FY, Huang YJ, Lin MC, Chen CF, et al. Solitary pulmonary nodules differentiated by dynamic F-18 FDG PET in a region with high prevalence of granulomatous disease. *J Radiat Res* 2012; **53**: 306-12. doi: 10.1269/jrr.11089
27. Yuan X, Zhang J, Quan C, Cao J, Ao G, Tian Y, et al. Differentiation of malignant and benign pulmonary nodules with first-pass dual-input perfusion CT. *Eur Radiol* 2013; **23**: 2469-74. doi: 10.1007/s00330-013-2842-x
28. Ohno Y, Koyama H, Fujisawa Y, Yoshikawa T, Seki S, Sugihara N, et al. Dynamic contrast-enhanced perfusion area detector CT for non-small cell lung cancer patients: influence of mathematical models on early prediction capabilities for treatment response and recurrence after chemoradiotherapy. *Eur J Radiol* 2016; **85**: 176-86. doi: 10.1016/j.ejrad.2015.11.009
29. Ohno Y, Nishio M, Koyama H, Fujisawa Y, Yoshikawa T, Matsumoto S, et al. Comparison of quantitatively analyzed dynamic area-detector CT using various mathematic methods with FDG PET/CT in management of solitary pulmonary nodules. *Am J Roentgenol* 2013; **200**: W593-602. doi: 10.2214/AJR.12.9197
30. Karakatsanis NA, Lodge MA, Tahari AK, Zhou Y, Wahl RL, Rahmim A. Dynamic whole-body PET parametric imaging: I. Concept, acquisition protocol optimization and clinical application. *Phys Med Biol* 2013; **58**: 7391-418. doi: 10.1088/0031-9155/58/20/7391
31. Dimitrakopoulou-Strauss A, Pan L, Strauss LG. Quantitative approaches of dynamic FDG-PET and PET/CT studies (dPET/CT) for the evaluation of oncological patients. *Cancer Imaging* 2012; **12**: 283-9. doi: 10.1102/1470-7330.2012.0033
32. Yi CA, Kyung SL, Kim BT, Joon YC, Kwon OJ, Kim H, et al. Tissue characterization of solitary pulmonary nodule: comparative study between helical dynamic CT and integrated PET/CT. *J Nucl Med* 2006; **47**: 443-50. PMID: 16513614
33. Ohno Y, Koyama H, Matsumoto K, Onishi Y, Takenaka D, Fujisawa Y, et al. Differentiation of malignant and benign pulmonary nodules with quantitative first-pass 320-detector row perfusion CT versus FDG PET/CT. *Radiology* 2011; **258**: 599-609. doi: 10.1148/radiol.10100245
34. Mirsadraee S, Reid JH, Connell M, MacNee W, Hirani N, Murchison JT, et al. Dynamic (4D) CT perfusion offers simultaneous functional and anatomical insights into pulmonary embolism resolution. *Eur J Radiol* 2016; **85**: 1883-90. doi: 10.1016/j.ejrad.2016.08.018
35. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. *J Cereb Blood Flow Metab* 1983; **3**: 1-7. doi: 10.1038/jcbfm.1983.1
36. Evangelista L, Cuocolo A, Pace L, Mansi L, Del Vecchio S, Miletto P, et al. Performance of FDG-PET/CT in solitary pulmonary nodule based on pre-test likelihood of malignancy: results from the ITALIAN retrospective multicenter trial. *Eur J Nucl Med Mol Imaging* 2018; **45**: 1898-907. doi: 10.1007/s00259-018-4016-1
37. Weir-McCall JR, Harris S, Miles KA, Qureshi NR, Rintoul RC, Dizdarevic S, et al. Impact of solitary pulmonary nodule size on qualitative and quantitative assessment using 18F-fluorodeoxyglucose PET/CT: the SPUTNIK trial. *Eur J Nucl Med Mol Imaging* 2020; **48**: 1560-9. doi: 10.1007/s00259-020-05089-y
38. Sim YT, Poon FW. Imaging of solitary pulmonary nodule-a clinical review. *Quant Imaging Med Surg* 2013; **3**: 316-26. doi: 10.3978/j.issn.2223-4292.2013.12.08
39. Ambrosini V, Nicolini S, Caroli P, Nanni C, Massaro A, Marzola MC, et al. PET/CT imaging in different types of lung cancer: an overview. *Eur J Radiol* 2012; **81**: 988-1001. doi: 10.1016/j.ejrad.2011.03.020
40. Chen CJ, Lee BF, Yao WJ, Cheng L, Wu PS, Ching LC, et al. Dual-phase 18F-FDG PET in the diagnosis of pulmonary nodules with an initial standard uptake value less than 2.5. *Am J Roentgenol* 2008; **191**: 475-9. doi: 10.2214/AJR.07.3457
41. Cloran FJ, Banks KP, Song WS, Kim Y, Bradley YC. Limitations of dual time point PET in the assessment of lung nodules with low FDG avidity. *Lung Cancer* 2010; **68**: 66-71. doi: 10.1016/j.lungcan.2009.05.013
42. Chiu CH, Yeh YC, Lin KH, Wu YC, Lee YC, Chou TY, et al. Histological subtypes of lung adenocarcinoma have differential 18F-fluorodeoxyglucose uptakes on the positron emission tomography/computed tomography scan. *J Thorac Oncol* 2011; **6**: 1697-703. doi: 10.1097/JTO.0b013e318226b677
43. Veronesi G, Bellomi M, Veronesi U, Paganelli G, Maisonneuve P, Scanagatta P, et al. Role of positron emission tomography scanning in the management of lung nodules detected at baseline computed tomography screening. *Ann Thorac Surg* 2007; **84**: 959-66. doi: 10.1016/j.athoracsur.2007.04.058
44. Nomori H, Watanabe K, Ohtsuka T, Naruke T, Suemasu K, Uno K. Evaluation of F-18 fluorodeoxyglucose (FDG) PET scanning for pulmonary nodules less than 3 cm in diameter, with special reference to the CT images. *Lung Cancer* 2004; **45**: 19-27. doi: 10.1016/j.lungcan.2004.01.009
45. Berger KL, Nicholson SA, Dehdashti F, Siegel BA. FDG PET evaluation of mucinous neoplasms: Correlation of FDG uptake with histopathologic features. *Am J Roentgenol* 2000; **174**: 1005-8. doi: 10.2214/ajr.174.4.1741005
46. Yi CA, Lee KS, Kim EA, Han J, Kim H, Kwon OJ, et al. Solitary pulmonary nodules: Dynamic enhanced multi-detector row CT study and comparison with vascular endothelial growth factor and microvessel density. *Radiology* 2004; **233**: 191-9. doi: 10.1148/radiol.2331031535
47. Zhang M, Kono M. Solitary pulmonary nodules: Evaluation of blood flow patterns with dynamic CT. *Radiology* 1997; **205**: 471-8. doi: 10.1148/radiology.205.2.9356631
48. Hornick JL, Fletcher CDM. PEComa: What do we know so far? *Histopathology* 2006; **48**: 75-82. doi: 10.1111/j.1365-2559.2005.02316.x
49. Stallmann S, Fisseler-Eckhoff A. [Mesenchymal tumors of the lungs]. [German]. *Pneumologie* 2014; **12**: 34-43. doi: 10.1007/s10405-014-0808-6
50. Chakrabarti A, Bandyopadhyay M, Purkayastha B. Malignant perivascular epithelioid cell tumour (PEComa) of the lung-A rare entity. *Innov Surg Sci* 2020; **2**: 39-42. doi: 10.1515/iss-2016-0032
51. Kim WJ, Kim SR, Choe YH, Lee KY, Park SJ, Lee HB, et al. Clear cell "sugar" tumor of the lung: a well-enhanced mass with an early washout pattern on dynamic contrast-enhanced computed tomography. *J Korean Med Sci* 2008; **23**: 1121-4. doi: 10.3346/jkms.2008.23.6.1121
52. Suljic A, Tomse P, Jensterle L, Skrk D. The impact of reconstruction algorithms and time of flight information on PET/CT image quality. *Radiol Oncol* 2015; **49**: 227-33. doi: 10.1515/raon-2015-0014
53. Bhalla A, Das A, Naranje P, Irodi A, Raj V, Goyal A. Imaging protocols for CT chest: a recommendation. *Indian J Radiol Imaging* 2019; **29**: 236. doi: 10.4103/ijri.ijri_34_19
54. Dolde K, Naumann P, Dávid C, Kachelriess M, Lomax AJ, Weber DC, et al. Comparing the effectiveness and efficiency of various gating approaches for PBS proton therapy of pancreatic cancer using 4D-MRI datasets. *Phys Med Biol* 2019; **64**: 085011. doi: 10.1088/1361-6560/ab1175
55. McCollough CH, Primak AN, Braun N, Kofler J, Yu L, Christner J. Strategies for reducing radiation dose in CT. *Radiol Clin N Am* 2009; **47**: 27-40. doi: 10.1016/j.rcl.2008.10.006
56. Qureshi NR, Rintoul RC, Miles KA, George S, Harris S, Madden J, et al. Accuracy and cost-effectiveness of dynamic contrast-enhanced CT in the characterisation of solitary pulmonary nodules – The SPUTNIK study. *BMJ Open Respir Res* 2016; **3**: e000156. doi: 10.1136/bmjresp-2016-000156